Israel’s VBL Therapeutics (reported here previously) has been awarded a grant of up to $0.9 million by the Israel Innovation Authority.  It will support the Phase 3 study of VBL’s lead candidate VB-111 for the treatment of platinum-resistant ovarian cancer. … Continue reading →

Israel’s VBL Therapeutics has opened its new gene therapy production facility to manufacture VBL’s lead cancer therapy ofranergene obadenovec (VB-111), when finally approved. The Modiin gene therapy plant is one of the largest in the world, and the first in … Continue reading →

Professor Dror Harats, CEO of VBL Therapeutics on ILTV News described the Phase 2 results of VB-111. The treatment (now in Phase 3 trials) doubles survival time for brain tumor patients and ovarian cancer patients.  It works for most solid … Continue reading →

I reported previously (Dec 2013) that VB-111 from Israel’s Vascular Biogenics (VBL Therapeutics) had been fast-tracked by the US FDA for the treatment of GBM – aggressive brain cancer.  Meanwhile, VBL has announced that VB-111’s Phase 2 trial for thyroid … Continue reading →

I reported previously (Dec 2013) on Israel’s VBL Therapeutics (aka Vascular Biogenics) and its treatment VB-111 for brain cancer. VB-111 targets new blood vessels developed to feed the tumor. Also, delivering the treatment inside a virus triggers the immune system … Continue reading →

Israel’s VBL Therapeutics has developed VB-201 – the first of a new class of oral anti-inflammatories called Lecinoxoids. VB-201 has the potential to treat immune-inflammatory diseases such as Psoriasis, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis and more. The US … Continue reading →